Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer.
Publication
, Journal Article
Geradts, J
Published in: Methods Mol Med
2003
Duke Scholars
Published In
Methods Mol Med
DOI
ISSN
1543-1894
Publication Date
2003
Volume
74
Start / End Page
89 / 99
Location
United States
Related Subject Headings
- Retinoblastoma Protein
- Lung Neoplasms
- Immunoenzyme Techniques
- Humans
- Cyclin-Dependent Kinase Inhibitor p16
- Carcinoma, Small Cell
- 1115 Pharmacology and Pharmaceutical Sciences
- 0304 Medicinal and Biomolecular Chemistry
Citation
APA
Chicago
ICMJE
MLA
NLM
Geradts, J. (2003). Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer. Methods Mol Med, 74, 89–99. https://doi.org/10.1385/1-59259-323-2:89
Geradts, Joseph. “Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer.” Methods Mol Med 74 (2003): 89–99. https://doi.org/10.1385/1-59259-323-2:89.
Geradts J. Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer. Methods Mol Med. 2003;74:89–99.
Geradts, Joseph. “Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer.” Methods Mol Med, vol. 74, 2003, pp. 89–99. Pubmed, doi:10.1385/1-59259-323-2:89.
Geradts J. Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer. Methods Mol Med. 2003;74:89–99.
Published In
Methods Mol Med
DOI
ISSN
1543-1894
Publication Date
2003
Volume
74
Start / End Page
89 / 99
Location
United States
Related Subject Headings
- Retinoblastoma Protein
- Lung Neoplasms
- Immunoenzyme Techniques
- Humans
- Cyclin-Dependent Kinase Inhibitor p16
- Carcinoma, Small Cell
- 1115 Pharmacology and Pharmaceutical Sciences
- 0304 Medicinal and Biomolecular Chemistry